WebNov 20, 2009 · All relapses were in “unfavorable” risk patients: 5 per GHSG and 4 per EORTC criteria. Secondary therapy included chemotherapy followed by high dose therapy and stem cell support (n=3) and ABVD (n=2). Three pts died, 2 due to disease progression after second-line therapy and one due to metastatic colon cancer. 5 patients developed a … WebMay 19, 2011 · Inclusion Criteria: Hodgkin Lymphoma; CS I, II with risk factor (stage IIB with risk factor 1 or 2 are not included) large mediastinal mass (>1/3 of maximum …
Controversies in the management of early-stage Hodgkin lymphoma
WebSep 14, 2024 · The establishment of standardised response criteria has facilitated the development of PET-directed treatment. 1,2 The 2007 International ... The only trial to demonstrate non-inferiority of chemotherapy alone is the German Hodgkin Study Group (GHSG) HD17 trial. 9 Patients received two cycles of eBEACOPP plus two cycles of … WebMay 16, 2013 · Scans were considered “positive” if the London Deauville visual scale score was 3 or higher. 26 602 patients were randomly assigned: 33% were stage I and 67% were stage II; 68% were favorable by GHSG criteria and 63% were favorable by EORTC criteria. 75% of patients (420/565) had a negative interim PET and were randomly assigned to … bruno asl 400 lift
Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a …
WebJun 1, 2024 · Early stage Hodgkin lymphoma (ESHL) is highly curable, and patients have excellent long-term outcomes with contemporary treatment regimens. 1 Classifications used by the European Organization for Research and Treatment of Cancer, National Comprehensive Cancer Network, and German Hodgkin Study Group (GHSG) … Webthe GHSG criteria allow up to 2 sites of involvement and the EORTC and NCCN criteria allow for up to 3 sites. In addition, the GHSG criteria exclude patients with extranodal … WebJan 1, 2024 · The presence of bilateral cervical and mediastinal involvement is, by definition, three nodal areas, meeting German Hodgkin Study Group (GHSG) criteria 2 for unfavourable disease; with joint criteria from the European Organisation for Research and Treatment of Cancer (EORTC) and Lymphoma Study Association (LYSA), 2 at least four … bruno asl-250 specs